108 related articles for article (PubMed ID: 8770772)
1. Effectiveness and toxicity of protracted nitric oxide synthesis inhibition during IL-2 treatment of mice.
Samlowski WE; Yim CY; McGregor JR; Kwon OD; Gonzales S; Hibbs JB
J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):166-78. PubMed ID: 8770772
[TBL] [Abstract][Full Text] [Related]
2. Effects of nitric oxide (NO) synthesis inhibition on antitumor responses during interleukin-2 (IL-2) treatment of mice.
Yim CY; Lee CW; Choi SM; Park SS; Lee SJ; Kim JH; Song JS; Yoo WH; Kwak JY; Sohn MH
Korean J Intern Med; 1996 Jun; 11(2):93-100. PubMed ID: 8854644
[TBL] [Abstract][Full Text] [Related]
3. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice.
Kondapaneni M; McGregor JR; Salvemini D; Laubach VE; Samlowski WE
J Immunother; 2008 May; 31(4):325-33. PubMed ID: 18391763
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor.
Yim CY; McGregor JR; Kwon OD; Bastian NR; Rees M; Mori M; Hibbs JB; Samlowski WE
J Immunol; 1995 Nov; 155(9):4382-90. PubMed ID: 7594598
[TBL] [Abstract][Full Text] [Related]
5. Effects of N(g)-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice.
Orucevic A; Lala PK
Cancer Immunol Immunother; 1996 Jan; 42(1):38-46. PubMed ID: 8625365
[TBL] [Abstract][Full Text] [Related]
6. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.
Tilton RG; Chang KC; LeJeune WS; Stephan CC; Brock TA; Williamson JR
Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):689-96. PubMed ID: 10067972
[TBL] [Abstract][Full Text] [Related]
7. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.
Orucevic A; Lala PK
Br J Cancer; 1996 Jan; 73(2):189-96. PubMed ID: 8546905
[TBL] [Abstract][Full Text] [Related]
8. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome.
Samlowski WE; Kondapaneni M; Tharkar S; McGregor JR; Laubach VE; Salvemini D
J Immunother; 2011 Jun; 34(5):419-27. PubMed ID: 21577143
[TBL] [Abstract][Full Text] [Related]
9. Effects of N(G)-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, on IL-2-induced LAK cell generation in vivo and in vitro in healthy and tumor-bearing mice.
Orucevic A; Lala PK
Cell Immunol; 1996 Apr; 169(1):125-32. PubMed ID: 8612285
[TBL] [Abstract][Full Text] [Related]
10. NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs.
Kilbourn RG; Owen-Schaub LB; Cromeens DM; Gross SS; Flaherty MJ; Santee SM; Alak AM; Griffith OW
J Appl Physiol (1985); 1994 Mar; 76(3):1130-7. PubMed ID: 8005855
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells.
Chang MJ; Modzelewski RA; Russell DM; Johnson CS
Cancer Res; 1996 Feb; 56(4):886-91. PubMed ID: 8631029
[TBL] [Abstract][Full Text] [Related]
12. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin-2-induced capillary leak syndrome in healthy mice.
Orucevic A; Lala PK
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):210-20. PubMed ID: 8680649
[TBL] [Abstract][Full Text] [Related]
13. The role of active inducible nitric oxide synthase expression in the pathogenesis of capillary leak syndrome resulting from interleukin-2 therapy in mice.
Orucevic A; Hearn S; Lala PK
Lab Invest; 1997 Jan; 76(1):53-65. PubMed ID: 9010449
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine.
Kilbourn RG; Gross SS; Lodato RF; Adams J; Levi R; Miller LL; Lachman LB; Griffith OW
J Natl Cancer Inst; 1992 Jul; 84(13):1008-16. PubMed ID: 1376778
[TBL] [Abstract][Full Text] [Related]
15. Effect of in vivo inhibition of nitric oxide production in murine leishmaniasis.
Evans TG; Thai L; Granger DL; Hibbs JB
J Immunol; 1993 Jul; 151(2):907-15. PubMed ID: 8335918
[TBL] [Abstract][Full Text] [Related]
16. The intravenous administration of tumor necrosis factor alpha, interleukin 8 and macrophage-derived neutrophil chemotactic factor inhibits neutrophil migration by stimulating nitric oxide production.
Tavares-Murta BM; Cunha FQ; Ferreira SH
Br J Pharmacol; 1998 Aug; 124(7):1369-74. PubMed ID: 9723947
[TBL] [Abstract][Full Text] [Related]
17. Effects of a nitric oxide synthase inhibitor on pressor response to angiotensin II in conscious rats.
Maeda T; Yoshimura T; Ohshige A; Koyama H; Ito M; Okamura H
Artery; 1998; 23(1):1-9. PubMed ID: 10846613
[TBL] [Abstract][Full Text] [Related]
18. The demonstration of nitric oxide in cochlear blood vessels in vivo and in vitro: the role of endothelial nitric oxide in venular permeability.
Shi X; Nuttall AL
Hear Res; 2002 Oct; 172(1-2):73-80. PubMed ID: 12361868
[TBL] [Abstract][Full Text] [Related]
19. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
Rosenstein M; Ettinghausen SE; Rosenberg SA
J Immunol; 1986 Sep; 137(5):1735-42. PubMed ID: 3528289
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nitric oxide synthesis does not improve interleukin-2-mediated antitumor effects in vivo.
Leder GH; Oppenheim M; Rosenstein M; Shah N; Hoffman R; Lotze MT; Beger HG
Eur Surg Res; 1996; 28(3):167-78. PubMed ID: 8738527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
